Hair-loss risk linked to GLP-1 weight-loss drugs in large study

A BMJ study of about 50,000 patients finds that GLP-1 receptor agonists used for diabetes and obesity (Mounjaro, Wegovy, Ozempic) are linked to a higher risk of hair loss than other diabetes meds, with a 37% higher risk vs SGLT-2 inhibitors and 68% higher vs DPP-4 inhibitors; most hair loss is non-scarring and may relate to weight loss/caloric restriction and micronutrient changes, though regulators are reviewing safety signals; hair loss is usually not physically harmful but can affect quality of life.